This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on June 2, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
2-PAM Autoinjectors Project Bioshield
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The contract involves BARDA seeking a contractor for the late-stage clinical development and regulatory approval of 2-PAM autoinjectors, which are designed as a drug/device combination product to treat organophosphate poisoning, including exposure to nerve agents, applicable for both adult and pediatric populations. Additionally, the contract includes the procurement of these autoinjectors for the Strategic National Stockpile (SNS) and the CHEMPACK program. This presolicitation notice outlines the government's interest in advancing this important medical countermeasure to address chemical threats. The solicitation, titled "2-PAM Autoinjectors Project Bioshield," was posted on June 2, 2026, with a response deadline on June 16, 2026. It is managed by the Department of Health and Human Services under the BARDA office located in Washington, DC. The contract falls under the NAICS code 541714, indicating a focus on research and development in biotechnology. The notice does not specify any set-aside provisions. Points of contact include Erin Greninger as the primary contracting officer and Greg Smith as the secondary contact. The place of performance is in Washington, DC, reflecting the administrative and oversight location for this government-funded effort.
General Info
Agency
NAICS
Place of Performance
Washington, DC, 20024, USASet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Submission Closed
Organization & Contact Information
Full Description
This is a presoliciation notice for the following:
BARDA seeks late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program.
